Status:
COMPLETED
Study Evaluating Etanercept and Methotrexate in Plaque Psoriasis
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Psoriasis
Arthritis, Psoriatic
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to evaluate the efficacy to clear or almost clear the plaques in plaque psoriasis patients, treated with the combination etanercept and methotrexate compared to etanercept...
Eligibility Criteria
Inclusion
- Active plaque psoriasis involving \>10% body surface area and/or minimal screening PASI score 8.
- Methotrexate \>7.5 mg/week for the last 3 months
Exclusion
- Predominantly guttate, erythrodermic or pustular psoriasis
- Other skin conditions than psoriasis
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
End Date :
December 1 2006
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00161655
Start Date
April 1 2005
End Date
December 1 2006
Last Update
September 28 2009
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Fredriksberg Alle, Copenhagen, Denmark
2
Gentofte Amtsygehus, Hellerup, Denmark
3
Helsinki, Helsinki, Finland
4
Tampere, Pirkanmaa, Finland